HRP20240234T1 - Aminokiselinski spojevi i postupci za uporabu - Google Patents

Aminokiselinski spojevi i postupci za uporabu Download PDF

Info

Publication number
HRP20240234T1
HRP20240234T1 HRP20240234TT HRP20240234T HRP20240234T1 HR P20240234 T1 HRP20240234 T1 HR P20240234T1 HR P20240234T T HRP20240234T T HR P20240234TT HR P20240234 T HRP20240234 T HR P20240234T HR P20240234 T1 HRP20240234 T1 HR P20240234T1
Authority
HR
Croatia
Prior art keywords
amino
butyl
tetrahydro
naphthyridin
butanoic acid
Prior art date
Application number
HRP20240234TT
Other languages
English (en)
Croatian (hr)
Inventor
Jacob CHA
Chengguo DONG
Timothy HOM
Lan Jiang
Katerina Leftheris
Hui Li
David J. Morgans Jr.
Manuel Munoz
Maureen REILLY
Yajun Zheng
Christopher Bailey
Darren FINKELSTEIN
Original Assignee
Pliant Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics, Inc. filed Critical Pliant Therapeutics, Inc.
Publication of HRP20240234T1 publication Critical patent/HRP20240234T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HRP20240234TT 2018-03-07 2019-03-07 Aminokiselinski spojevi i postupci za uporabu HRP20240234T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862639988P 2018-03-07 2018-03-07
US201862690933P 2018-06-27 2018-06-27
EP19765136.7A EP3761980B1 (en) 2018-03-07 2019-03-07 Amino acid compounds and methods of use
PCT/US2019/021243 WO2019173653A1 (en) 2018-03-07 2019-03-07 Amino acid compounds and methods of use

Publications (1)

Publication Number Publication Date
HRP20240234T1 true HRP20240234T1 (hr) 2024-04-26

Family

ID=67844341

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240234TT HRP20240234T1 (hr) 2018-03-07 2019-03-07 Aminokiselinski spojevi i postupci za uporabu

Country Status (35)

Country Link
US (4) US10793564B2 (enExample)
EP (3) EP4328230A3 (enExample)
JP (4) JP6866535B2 (enExample)
KR (2) KR20250048478A (enExample)
CN (1) CN112135612B (enExample)
AU (1) AU2019230209B2 (enExample)
BR (1) BR112020018064A2 (enExample)
CA (1) CA3093225A1 (enExample)
CL (1) CL2020002290A1 (enExample)
CO (1) CO2020011085A2 (enExample)
CR (1) CR20200452A (enExample)
CU (1) CU24684B1 (enExample)
DK (1) DK3761980T3 (enExample)
EC (1) ECSP20063227A (enExample)
ES (1) ES2972512T3 (enExample)
FI (1) FI3761980T3 (enExample)
HR (1) HRP20240234T1 (enExample)
HU (1) HUE065887T2 (enExample)
IL (2) IL277146B2 (enExample)
JO (1) JOP20200212A1 (enExample)
LT (1) LT3761980T (enExample)
MD (1) MD3761980T2 (enExample)
MX (2) MX2020009253A (enExample)
PE (2) PE20201502A1 (enExample)
PH (1) PH12020551395A1 (enExample)
PL (1) PL3761980T3 (enExample)
PT (1) PT3761980T (enExample)
RS (1) RS65170B1 (enExample)
SA (1) SA520420102B1 (enExample)
SG (1) SG11202008609UA (enExample)
SI (1) SI3761980T1 (enExample)
SM (1) SMT202400155T1 (enExample)
TW (1) TWI892960B (enExample)
WO (1) WO2019173653A1 (enExample)
ZA (1) ZA202005437B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CU24684B1 (es) * 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
EP3952902A4 (en) * 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4076454A1 (en) * 2019-12-20 2022-10-26 Novartis AG Combination treatment of liver diseases using integrin inhibitors
KR20230049584A (ko) * 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료
TW202235417A (zh) * 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
US20230028658A1 (en) * 2021-04-30 2023-01-26 Pliant Therapeutics, Inc. Expanded dosage regimens for integrin inhibitors
WO2023225119A1 (en) * 2022-05-18 2023-11-23 Pliant Therapeutics, Inc. Stabilization of integrin inhibitors
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders
WO2024125634A1 (zh) * 2022-12-16 2024-06-20 西藏海思科制药有限公司 一种四氢萘啶类化合物及其在医药上的应用
WO2024155965A2 (en) * 2023-01-21 2024-07-25 Pliant Therapeutics, Inc. Biomarkers for use in integrin inhibitor therapy
WO2024235299A1 (zh) * 2023-05-17 2024-11-21 西藏海思科制药有限公司 一种羧基衍生物及其在医药上的应用
WO2025024590A1 (en) * 2023-07-24 2025-01-30 The Johns Hopkins University Compositions and methods to treat mucus-related diseases
WO2025067384A1 (zh) * 2023-09-28 2025-04-03 成都微芯药业有限公司 一类氨基酸整联蛋白抑制剂、其制备方法及其应用
US20250197393A1 (en) 2023-12-14 2025-06-19 Pliant Therapeutics, Inc. Integrin inhibitor and uses thereof
TW202615060A (zh) * 2024-06-21 2026-04-16 美商艾拉倫製藥公司 用於肝外遞送之整合素配體

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361764B2 (en) 1996-12-13 2002-03-26 Societe L'oreal S.A. Insoluble s-triazine derivatives and their use as UV filters
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
SK9192000A3 (en) 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
ATE396174T1 (de) 2001-06-01 2008-06-15 Elan Pharm Inc Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
AU2003273310A1 (en) 2002-09-10 2004-04-30 Pharmacia And Upjohn Substituted aminoethers for the treatment of alzheimer's disease
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
PL2299987T3 (pl) 2008-06-06 2018-08-31 Boehringer Ingelheim International Gmbh Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu
IN2015DN00099A (enExample) * 2012-07-18 2015-05-29 Univ Saint Louis
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
JP7170540B2 (ja) 2016-04-14 2022-11-14 マース インコーポレーテッド コク味を調節するためにカルシウム感知受容体活性を調節する化合物及びそれを含むペットフード製品
KR20190026001A (ko) * 2016-07-05 2019-03-12 더 락커펠러 유니버시티 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CU24684B1 (es) * 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
EP3843728B1 (en) 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
KR20230049584A (ko) 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료

Also Published As

Publication number Publication date
DK3761980T3 (da) 2024-01-29
IL277146B2 (en) 2024-02-01
IL277146B1 (en) 2023-10-01
JP2023106425A (ja) 2023-08-01
TW201938158A (zh) 2019-10-01
NZ767658A (en) 2024-11-29
JP2025081308A (ja) 2025-05-27
CU20200066A7 (es) 2021-04-07
US20210017171A1 (en) 2021-01-21
CN112135612A (zh) 2020-12-25
EP4328230A3 (en) 2024-04-24
FI3761980T3 (fi) 2024-02-21
LT3761980T (lt) 2024-03-12
EP4509512A3 (en) 2025-04-09
PL3761980T3 (pl) 2024-06-10
RS65170B1 (sr) 2024-02-29
EP3761980B1 (en) 2023-11-29
CR20200452A (es) 2020-11-19
ES2972512T3 (es) 2024-06-13
US20190276449A1 (en) 2019-09-12
JOP20200212A1 (ar) 2020-09-01
MX2020009253A (es) 2021-01-15
PH12020551395A1 (en) 2021-11-22
EP4509512A2 (en) 2025-02-19
IL305296A (en) 2023-10-01
BR112020018064A2 (pt) 2020-12-22
JP7624025B2 (ja) 2025-01-29
EP4328230A2 (en) 2024-02-28
WO2019173653A1 (en) 2019-09-12
CL2020002290A1 (es) 2021-01-15
IL277146A (en) 2020-10-29
MD3761980T2 (ro) 2024-09-30
PE20251320A1 (es) 2025-05-16
KR20200139676A (ko) 2020-12-14
US20230271960A1 (en) 2023-08-31
SG11202008609UA (en) 2020-10-29
US20250223288A1 (en) 2025-07-10
ZA202005437B (en) 2024-06-26
AU2019230209B2 (en) 2024-02-01
KR102787602B1 (ko) 2025-03-31
PT3761980T (pt) 2024-02-29
KR20250048478A (ko) 2025-04-08
MX2022014456A (es) 2022-12-08
HUE065887T2 (hu) 2024-06-28
JP7273882B2 (ja) 2023-05-15
JP6866535B2 (ja) 2021-04-28
JP2021119140A (ja) 2021-08-12
AU2019230209A1 (en) 2020-09-24
SA520420102B1 (ar) 2024-10-20
SMT202400155T1 (it) 2024-05-14
US10793564B2 (en) 2020-10-06
CN112135612B (zh) 2025-06-17
PE20201502A1 (es) 2020-12-29
CO2020011085A2 (es) 2020-12-10
CU24684B1 (es) 2023-10-06
SI3761980T1 (sl) 2024-06-28
ECSP20063227A (es) 2020-11-30
EP3761980A4 (en) 2021-10-27
US11560376B2 (en) 2023-01-24
TWI892960B (zh) 2025-08-11
JP2021509890A (ja) 2021-04-08
CA3093225A1 (en) 2019-09-12
EP3761980A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
FI3761980T3 (fi) Aminohappoyhdisteitä ja käyttömenetelmiä
JP2021119140A5 (enExample)
AU2022204166C1 (en) 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
JP2022526818A5 (enExample)
AU2019374812B2 (en) Pyridazinone compounds and uses thereof
HRP20240994T1 (hr) Spoj inhibitora jak i njegova uporaba
JP2019048878A (ja) Kitに関連する疾患を治療するために有用な組成物
JP2013523710A5 (enExample)
RU2019105587A (ru) Макроциклические ингибиторы киназ
HRP20221154T1 (hr) Supstituirani pirazolo[1,5-a]piridinski spojevi kao inhibitori ret kinaze
JP2017531039A5 (enExample)
HRP20161203T1 (hr) Novi derivati tienopirimidina, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
JP2019503337A5 (enExample)
ME02880B (me) Derivati 5-fluoro- n- (piridin -2-il}piridi n- 2 - amina koji sadrze sulfoksiminsku grupu
HRP20200107T1 (hr) Novi derivati hidroksiestera, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
ME02811B (me) Amino-supstituisani imidazo[1, 2-a]piridinkarboksamidi i njihova primena
JP2016522231A5 (enExample)
JP2016514717A5 (enExample)
JP2007528394A5 (enExample)
JP2015528018A5 (enExample)
RU2013130907A (ru) Замещенные имидазохинолиновые производные
JP2018508553A5 (enExample)
RU2014109748A (ru) Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor
EP1865959A2 (en) Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives